Ziyou Lin

State Key Laboratory Of Oncology In South China
Guangzhou, 510060, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

The IGF2BP3-FASN axis drives lipid metabolic reprogramming to promote brain colonization in non-small cell lung cancer.

The IGF2BP3-FASN axis drives lipid metabolic reprogramming to promote brain colonization in non-small cell lung cancer.

Journal: Cell death & disease

Published: February 08, 2025

Discovery and Optimization of Novel Biphenyl Derivatives Bearing Cyclopropyl Linkage as Potent Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors.

Discovery and Optimization of Novel Biphenyl Derivatives Bearing Cyclopropyl Linkage as Potent Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors.

Journal: Journal of medicinal chemistry

Published: May 09, 2023

Reprogramming of TAMs via the STAT3/CD47-SIRPα axis promotes acquired resistance to EGFR-TKIs in lung cancer.

Reprogramming of TAMs via the STAT3/CD47-SIRPα axis promotes acquired resistance to EGFR-TKIs in lung cancer.

Journal: Cancer letters

Published: January 16, 2023

Targeting STAT3-VISTA axis to suppress tumor aggression and burden in acute myeloid leukemia.

Targeting STAT3-VISTA axis to suppress tumor aggression and burden in acute myeloid leukemia.

Journal: Journal of hematology & oncology

Published: December 16, 2022

Metabolic Reprogramming Driven by IGF2BP3 Promotes Acquired Resistance to EGFR Inhibitors in Non-Small Cell Lung Cancer.

Metabolic Reprogramming Driven by IGF2BP3 Promotes Acquired Resistance to EGFR Inhibitors in Non-Small Cell Lung Cancer.

Journal: Cancer research

Published: September 27, 2022

Inhibition of STAT3-ferroptosis negative regulatory axis suppresses tumor growth and alleviates chemoresistance in gastric cancer.

Inhibition of STAT3-ferroptosis negative regulatory axis suppresses tumor growth and alleviates chemoresistance in gastric cancer.

Journal: Redox biology

Published: January 22, 2022

N6-methyladenosine demethylase FTO enhances chemo-resistance in colorectal cancer through SIVA1-mediated apoptosis.

N6-methyladenosine demethylase FTO enhances chemo-resistance in colorectal cancer through SIVA1-mediated apoptosis.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: January 09, 2022

Loss-of-Function Genetic Screening Identifies Aldolase A as an Essential Driver for Liver Cancer Cell Growth Under Hypoxia.

Loss-of-Function Genetic Screening Identifies Aldolase A as an Essential Driver for Liver Cancer Cell Growth Under Hypoxia.

Journal: Hepatology (Baltimore, Md.)

Published: May 27, 2020

RNA-binding protein RALY reprogrammes mitochondrial metabolism via mediating miRNA processing in colorectal cancer.

RNA-binding protein RALY reprogrammes mitochondrial metabolism via mediating miRNA processing in colorectal cancer.

Journal: Gut

Published: January 10, 2020

RNA m6 A methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy.

RNA m6 A methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy.

Journal: The EMBO journal

Published: August 08, 2019

RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3.

RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3.

Journal: Molecular cancer

Published: January 04, 2019

N 6-Methyladenosine modification: a novel pharmacological target for anti-cancer drug development.

N 6-Methyladenosine modification: a novel pharmacological target for anti-cancer drug development.

Journal: Acta pharmaceutica Sinica. B

Published: April 10, 2018

Showing 1-12 of 12

Last Updated: 09/26/2026